Previous close | 0.0614 |
Open | 0.0646 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0646 - 0.0646 |
52-week range | 0.0614 - 0.1305 |
Volume | |
Avg. volume | 13 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 29 May 2024 - 02 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Hydreight Technologies announced the addition of Tirzepatide to its weight loss portfolio which also includes GLP-1 injections, giving patients a cost-effective way to access safe, high quality diabetes and weight loss treatment through the Hydreight platform and its associated Medical network in over 700 cities across 50 states in the USVANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company tha
A diverse portfolio of 25+ innovative companies from around the world (founders from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America)Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate TechRevenue for the year ended December 31, 2023, was $12,055,070 compared to $5,929,096 for the corresponding prior year period.Cash & liquid securities approx. $4,903
A diverse portfolio of 25+ innovative companies from around the world (founders from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America)Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate TechRevenue for the year ended December 31, 2023, was $12,055,070 compared to $5,929,096 for the corresponding prior year periodCash & liquid securities approx. $4,903,